{"article_title": "Dr. Reddy's Builds Drug Portfolio with Belgian Brands", "article_keywords": ["pharmaceutical", "ucb", "builds", "xyzal", "company", "india", "drug", "services", "reddys", "brands", "portfolio", "dr", "belgian"], "article_url": "http://www.themiddlemarket.com/news/healthcare/dr-reddys-builds-drug-portfolio-with-belgian-brands-256895-1.html", "article_text": "Dr. Reddy's Builds Drug Portfolio with Belgian Brands\n\nThe deal comes days after GTCR picked up pharma management software company Transaction Data\n\nPharmaceutical company Dr. Reddy's Laboratories Ltd., which has offices in Princeton, New Jersey, completed the acquisition of select portfolio of established brands of Belgian firm UCB in India.\n\nDr. Reddy\u0092s has said the acquired UCB portfolio would accelerate its presence in the high growth areas of dermatology, respiratory and pediatrics, with brands such as Atarax, Nootropil, Zyrtec, Xyzal and Xyzal M. The company originally announced in April that it would acquire select portfolio of established brands of UCB in India, Nepal, Sri Lanka and Maldives for Rs. 800 crore ($130 million).\n\nThe company had entered into a definitive agreement with UCB which also entails absorbing 350 employees engaged in the operations of India business.\n\nDr. Reddy's is based in Princeton, New Jersey and Telangana, India. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.\n\nThe deal was announced just days after GTCR invested in Transaction Data Systems Inc., a pharmacy management software company that does business as Rx30. Ocoee, Florida-based Rx30 develops pharmacy-management programs for hospital, long-term care and the specialty pharmaceutical markets.\n\nFor more information on related topics, visit the following:", "article_metadata": {"og": {"url": "http://www.themiddlemarket.com/news/healthcare/dr-reddys-builds-drug-portfolio-with-belgian-brands-256895-1.html", "image": "http://cdn.themiddlemarket.com/media/newspics/Dr_Reddy_snippet.jpg", "site_name": "Mergers & Acquisitions, Latest News", "title": "Dr. Reddy's Builds Drug Portfolio with Belgian Brands"}}, "_id": "\"57477af36914bd0286fca3b1\"", "article_summary": "Dr. Reddy's Builds Drug Portfolio with Belgian BrandsThe deal comes days after GTCR picked up pharma management software company Transaction DataPharmaceutical company Dr. Reddy's Laboratories Ltd., which has offices in Princeton, New Jersey, completed the acquisition of select portfolio of established brands of Belgian firm UCB in India.\nThrough its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.\nDr. Reddy's is based in Princeton, New Jersey and Telangana, India.\nThe company had entered into a definitive agreement with UCB which also entails absorbing 350 employees engaged in the operations of India business.\nDr. Reddy\u0092s has said the acquired UCB portfolio would accelerate its presence in the high growth areas of dermatology, respiratory and pediatrics, with brands such as Atarax, Nootropil, Zyrtec, Xyzal and Xyzal M. The company originally announced in April that it would acquire select portfolio of established brands of UCB in India, Nepal, Sri Lanka and Maldives for Rs."}